-
May 3, 2024 | 00140-2/abstract&sz=64)
thelancet.com | S List |Bob Li |Funda Meric-Bernstam |Aditya Bardia
1. Najjar MK Manore SG Regua AT Lo H-W Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes. 2022; 1320652. Essadi I Benbrahim Z Kaakoua M Reverdy T Corbaux P Freyer G HER2-positive metastatic breast cancer: available treatments and current developments. Cancers. 2023; 1517383. Abrahão-Machado LF Jácome AA Wohnrath DR et al. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol.
-
Mar 3, 2024 | 
nature.com | Vivek Subbiah |Mohamed A. Gouda |Maria E Cabanillas |Behrang Amini |Funda Meric-Bernstam
AbstractPatients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management because of multiple potential mechanisms and the unclear tolerability of drug combinations. A patient with metastatic medullary thyroid carcinoma (MTC) harboring a RET activation loop D898_E901del mutation was treated with selpercatinib.
-
Nov 1, 2023 | 
onclive.com | Funda Meric-Bernstam
Funda Meric-Bernstam, MD, chair, the Department of Investigational Cancer Therapeutics–the Phase I Program, medical director, the Institute for Personalized Cancer Therapy (IPCT), the Nellie B. Connally Chair in Breast Cancer, the University of Texas MD Anderson Cancer Center, discusses results from the phase 2 DESTINY-PanTumor02 trial (NCT04482309) of fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in patients with HER2-expressing solid tumors.
-
Aug 18, 2023 | 
healio.com | Drew Amorosi |Mindy Valcarcel |Funda Meric-Bernstam |Adam Brufsky
Source/Disclosures
Source:
Healio Interviews
Disclosures:
Disclosures: Brufsky reports advisory board roles with AstraZeneca, Daiichi Sankyo and Gilead Sciences. Kim reports consultant roles with Genentech/Roche and Mirati Therapeutics.
-
Aug 7, 2023 | 
targetedonc.com | Funda Meric-Bernstam
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center, discusses the phase 2 DESTINY-PanTumor02 trial (NCT04482309) of fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with HER2-low breast cancer, HER2-positive breast cancer, HER2-positive gastric cancer, and HER2-mutant lung cancer. Trastuzumab deruxtecan is a potent antibody-drug conjugate.
-
Jul 14, 2023 | 
targetedonc.com | Funda Meric-Bernstam
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center, discusses fam-trastuzumab deruxtecan-nxki (Enhertu) and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial (NCT04482309). Currently, trastuzumab deruxtecan is the standard of care for patients withHER2-low breast cancer, HER2-positive breast cancer, HER2-positive gastric cancer, and HER2-mutant lung cancer.
-
Jun 28, 2023 | 
onclive.com | Funda Meric-Bernstam
Funda Meric-Bernstam, MD, chair, the Department of Investigational Cancer Therapeutics–the Phase I Program, medical director, the Institute for Personalized Cancer Therapy (IPCT), the Nellie B. Connally Chair in Breast Cancer, the University of Texas MD Anderson Cancer Center, discusses a first-in-human phase 1/2 study (NCT04902872) of CBX-12 in patients with advanced or metastatic solid tumors.
-
Jun 7, 2023 | 
onclive.com | Funda Meric-Bernstam
Funda Meric-Bernstam, MD, chair, the Department of Investigational Cancer Therapeutics–the Phase I Program, medical director, the Institute for Personalized Cancer Therapy (IPCT), the Nellie B. Connally Chair in Breast Cancer, the University of Texas MD Anderson Cancer Center, discusses the phase 2 DESTINY-PanTumor02 trial (NCT04482309) of fam-trastuzumab deruxtecan-nxki (Enhertu) in difficult-to-treat HER2-positive solid tumors.
-
Jun 5, 2023 | 
healio.com | Devin McLaughlin |Funda Meric-Bernstam |Bradley Alexander McGregor
Source/Disclosures
Source:
Meric-Bernstam F, et al. Abstract LBA3000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Disclosures:
AstraZeneca and Daiichi Sankyo supported this study.
-
Apr 18, 2023 | 
nature.com | Omar Alhalabi |Roman Groisberg |Andrew Hahn |Aung Naing |Apostolia M. Tsimberidou |Timothy A. Yap | +2 more
AbstractPre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel. Primary objective was safety and secondary objectives were clinical response and survival. One patient had a dose-limiting toxicity at dose level 4. There were no unanticipated toxicities.
